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Abstract
The Concise Guide to PHARMACOLOGY 2019/20 is the fourth in this series of biennial publications. The Concise Guide provides concise overviews of the key properties of nearly 1800 human
drug targets with an emphasis on selective pharmacology (where available), plus links to the open access knowledgebase source of drug targets and their ligands (www.guidetopharmacology.org),
which provides more detailed views of target and ligand properties. Although the Concise Guide represents approximately 400 pages, the material presented is substantially reduced compared
to information and links presented on the website. It provides a permanent, citable, point-in-time record that will survive database updates. The full contents of this section can be found at
http://onlinelibrary.wiley.com/doi/10.1111/bph.14747. In addition to this overview, in which are identiﬁed Other protein targets which fall outside of the subsequent categorisation, there are six
areas of focus: G protein-coupled receptors, ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary
information on the best available pharmacological tools, alongside key references and suggestions for further reading. The landscape format of the Concise Guide is designed to facilitate comparison
of related targets from material contemporary to mid-2019, and supersedes data presented in the 2017/18, 2015/16 and 2013/14 Concise Guides and previous Guides to Receptors and Channels. It is
produced in close conjunction with the International Union of Basic and Clinical Pharmacology Committee on Receptor Nomenclature and Drug Classiﬁcation (NC-IUPHAR), therefore, providing ofﬁcial
IUPHAR classiﬁcation and nomenclature for human drug targets, where appropriate.
Searchable database: http://www.guidetopharmacology.org/index.jsp Other protein targets S1
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14747/full
(2019) 176, S1–S20Introduction
Table of contents
S1 Introduction and Other Protein Targets
S6 Adiponectin receptors
S7 Blood coagulation components
S8 Non-enzymatic BRD containing proteins
S9 Carrier proteins
S9 CD molecules
S11 Methyllysine reader proteins
S11 Fatty acid-binding proteins
S14 Notch receptors
S15 Regulators of G protein Signaling (RGS) proteins
S18 Sigma receptors
S19 Tubulins
S21 G protein-coupled receptors
S23 Orphan and other 7TM receptors
S24 Class A Orphans
S26 Class C Orphans
S33 Taste 1 receptors
S34 Taste 2 receptors
S35 Other 7TM proteins
S36 5-Hydroxytryptamine receptors
S39 Acetylcholine receptors (muscarinic)
S41 Adenosine receptors
S42 Adhesion Class GPCRs
S45 Adrenoceptors
S48 Angiotensin receptors
S50 Apelin receptor
S51 Bile acid receptor
S51 Bombesin receptors
S53 Bradykinin receptors
S54 Calcitonin receptors
S56 Calcium-sensing receptor
S57 Cannabinoid receptors
S58 Chemerin receptors
S59 Chemokine receptors
S63 Cholecystokinin receptors
S64 Class Frizzled GPCRs
S67 Complement peptide receptors
S68 Corticotropin-releasing factor receptors
S69 Dopamine receptors
S71 Endothelin receptors
S72 G protein-coupled estrogen receptor
S73 Formylpeptide receptors
S74 Free fatty acid receptors
S76 GABAB receptors
S78 Galanin receptors
S79 Ghrelin receptor
S80 Glucagon receptor family
S81 Glycoprotein hormone receptors
S82 Gonadotrophin-releasing hormone receptors
S83 GPR18, GPR55 and GPR119
S84 Histamine receptors
S86 Hydroxycarboxylic acid receptors
S87 Kisspeptin receptor
S88 Leukotriene receptors
S89 Lysophospholipid (LPA) receptors
S90 Lysophospholipid (S1P) receptors
S92 Melanin-concentrating hormone receptors
S93 Melanocortin receptors
S94 Melatonin receptors
S95 Metabotropic glutamate receptors
S97 Motilin receptor
S98 Neuromedin U receptors
S99 Neuropeptide FF/neuropeptide AF receptors
S100 Neuropeptide S receptor
S101 Neuropeptide W/neuropeptide B receptors
S102 Neuropeptide Y receptors
S103 Neurotensin receptors
S104 Opioid receptors
S106 Orexin receptors
S107 Oxoglutarate receptor
S108 P2Y receptors
S110 Parathyroid hormone receptors
S111 Platelet-activating factor receptor
S112 Prokineticin receptors
S113 Prolactin-releasing peptide receptor
S114 Prostanoid receptors
S116 Proteinase-activated receptors
S117 QRFP receptor
S118 Relaxin family peptide receptors
S120 Somatostatin receptors
S121 Succinate receptor
S122 Tachykinin receptors
S123 Thyrotropin-releasing hormone receptors
S124 Trace amine receptor
S125 Urotensin receptor
S126 Vasopressin and oxytocin receptors
S127 VIP and PACAP receptors
S142 Ion channels
S143 Ligand-gated ion channels
S144 5-HT receptors3
S146 Acid-sensing (proton-gated) ion channels (ASICs)
S148 Epithelial sodium channel (ENaC)
S149 GABA receptorsA
S155 Glycine receptors
S158 Ionotropic glutamate receptors
S164 IP receptor3
S165 Nicotinic acetylcholine receptors
S168 P2X receptors
S170 ZAC
S171 Voltage-gated ion channels
S171 CatSper and Two-Pore channels
S173 Cyclic nucleotide-regulated channels
S175 Potassium channels
S175 Calcium- and sodium-activated potassium channels
S178 Inwardly rectifying potassium channels
S182 Two P domain potassium channels
S185 Voltage-gated potassium channels
S189 Ryanodine receptors
S190 Transient Receptor Potential channels
S204 Voltage-gated calcium channels
S207 Voltage-gated proton channel
S208 Voltage-gated sodium channels
S210 Aquaporins
S212 Chloride channels
S213 ClC family
S215 CFTR
S216 Calcium activated chloride channel
S217 Maxi chloride channel
S218 Volume regulated chloride channels
S219 Connexins and Pannexins
S221 Piezo channels
S222 Sodium leak channel, non-selective
S229 Nuclear hormone receptors
S230 1A. Thyroid hormone receptors
S231 1B. Retinoic acid receptors
S232 1C. Peroxisome proliferator-activated receptors
S233 1D. Rev-Erb receptors
S234 1F. Retinoic acid-related orphans
S234 1H. Liver X receptor-like receptors
S235 1I. Vitamin D receptor-like receptors
S236 2A. Hepatocyte nuclear factor-4 receptors
S237 2B. Retinoid X receptors
S238 2C. Testicular receptors
S238 2E. Tailless-like receptors
S239 2F. COUP-TF-like receptors
S239 3B. Estrogen-related receptors
S240 4A. Nerve growth factor IB-like receptors
Searchable database: http://www.guidetopharmacology.org/index.jsp Other protein targets S2
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14747/full
S210 Other ion channels
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: and Other Protein Targets. British Journal of Pharmacology (2019) 176, S1–S20Introduction
S241 6A. Germ cell nuclear factor receptors
S242 0B. DAX-like receptors
S242 Steroid hormone receptors
S243 3A. Estrogen receptors
S244 3C. 3-Ketosteroid receptors
S247 Catalytic receptors
S248 Cytokine receptor family
S249 IL-2 receptor family
S251 IL-3 receptor family
S252 IL-6 receptor family
S254 IL-12 receptor family
S255 Prolactin receptor family
S256 Interferon receptor family
S257 IL-10 receptor family
S258 Immunoglobulin-like family of IL-1 receptors
S259 IL-17 receptor family
S259 GDNF receptor family
S260 Integrins
S264 Pattern recognition receptors
S264 Toll-like receptor family
S266 NOD-like receptor family
S268 RIG-I-like receptor family
S271 Receptor tyrosine kinases (RTKs)
S272 Type I RTKs: ErbB (epidermal growth factor) receptor family
S273 Type II RTKs: Insulin receptor family
S274 Type III RTKs: PDGFR, CSFR, Kit, FLT3 receptor family
S275 Type IV RTKs: VEGF (vascular endothelial growth factor)
receptor family
S275 Type V RTKs: FGF (broblast growth factor) receptor family
S276 Type VI RTKs: PTK7/CCK4
S277 Type VII RTKs: Neurotrophin receptor/Trk family
S278 Type VIII RTKs: ROR family
S278 Type IX RTKs: MuSK
S279 Type X RTKs: HGF (hepatocyte growth factor) receptor family
S279 Type XI RTKs: TAM (TYRO3-, AXL- and MER-TK)
receptor family
S280 Type XII RTKs: TIE family of angiopoietin receptors
S280 Type XIII RTKs: Ephrin receptor family
S281 Type XIV RTKs: RET
S282 Type XV RTKs: RYK
S282 Type XVI RTKs: DDR (collagen receptor) family
S283 Type XVII RTKs: ROS receptors
S283 Type XVIII RTKs: LMR family
S284 Type XIX RTKs: Leukocyte tyrosine kinase (LTK) receptor
family
S284 Type XX RTKs: STYK1
S286 Receptor serine/threonine kinase (RSTK) family
S287 Type II receptor serine/threonine kinases
S287 Type III receptor serine/threonine kinases
S287 RSTK functional heteromers
S289 Receptor tyrosine phosphatase (RTP) family
S291 Tumour necrosis factor (TNF) receptor family
S297 Enzymes
S301 Acetylcholine turnover
S302 Adenosine turnover
S303 Amino acid hydroxylases
S304 L-Arginine turnover
S304 2.1.1.- Protein arginine N-methyltransferases
S305 Arginase
S305 Arginine:glycine amidinotransferase
S305 Dimethylarginine dimethylaminohydrolases
S306 Nitric oxide synthases
S307 Carbonic anhydrases
S308 Carboxylases and decarboxylases
S308 Carboxylases
S309 Decarboxylases
S311 Catecholamine turnover
S313 Ceramide turnover
S313 Serine palmitoyltransferase
S314 Ceramide synthase
S314 Sphingolipid  4-desaturase
S315 Sphingomyelin synthase
S315 Sphingomyelin phosphodiesterase
S316 Neutral sphingomyelinase coupling factors
S316 Ceramide glucosyltransferase
S316 Acid ceramidase
S317 Neutral ceramidases
S317 Alkaline ceramidases
S318 Ceramide kinase
S319 Chromatin modifying enzymes
S319 2.1.1.- Protein arginine N-methyltransferases
S320 3.5.1.- Histone deacetylases (HDACs)
S321 Cyclic nucleotide turnover/signalling
S321 Adenylyl cyclases (ACs)
S323 Exchange protein activated by cyclic AMP (EPACs)
S270 Nitric oxide (NO)-sensitive (soluble) guanylyl cyclase
S323 Phosphodiesterases, 3’,5’-cyclic nucleotide (PDEs)
S327 Cytochrome P450
S327 CYP2 family
S329 CYP3 family
S330 CYP4 family
S331 CYP5, CYP7 and CYP8 families
S332 CYP11, CYP17, CYP19, CYP20 and CYP21 families
S333 CYP24, CYP26 and CYP27 families
S333 CYP39, CYP46 and CYP51 families
S334 DNA topoisomerases
S335 Endocannabinoid turnover
S336 N-Acylethanolamine turnover
S337 2-Acylglycerol ester turnover
S338 Eicosanoid turnover
S338 Cyclooxygenase
S339 Prostaglandin synthases
S341 Lipoxygenases
S342 Leukotriene and lipoxin metabolism
S343 GABA turnover
S344 Glycerophospholipid turnover
S345 Phosphoinositide-speciﬁc phospholipase C
S346 Phospholipase A2
S348 Phosphatidylcholine-speciﬁc phospholipase D
S349 Lipid phosphate phosphatases
S349 Phosphatidylinositol kinases
S356 Phosphatidylinositol phosphate kinases
S356 Haem oxygenase
S358 Hydrogen sulphide synthesis
S358 Hydrolases
S360 Inositol phosphate turnover
S360 Inositol 1,4,5-trisphosphate 3-kinases
S360 Inositol polyphosphate phosphatases
S361 Inositol monophosphatase
S361 Kinases (EC 2.7.x.x)
S362 Rho kinase
S362 Protein kinase C (PKC) family
S363 Alpha subfamily
S363 Delta subfamily
S364 Eta subfamily
S364 FRAP subfamily
S365 Cyclin-dependent kinase (CDK) family
S365 CDK4 subfamily
S366 GSK subfamily
S350 1-phosphatidylinositol 4-kinase family
S351 Phosphatidylinositol-4-phosphate 3-kinase family
S351 Phosphatidylinositol 3-kinase family
S351 Phosphatidylinositol-4,5-bisphosphate 3-kinase family
S352 1-phosphatidylinositol-3-phosphate 5-kinase family
S353 Type I PIP kinases (1-phosphatidylinositol-4-phosphate
5-kinase family)
S353 Type II PIP kinases (1-phosphatidylinositol-5-phosphate 4-
kinase family)
S354 Sphingosine kinase
S367 Polo-like kinase (PLK) family
S367 STE7 family
S368 Abl family
S368 Ack family
Searchable database: http://www.guidetopharmacology.org/index.jsp Other protein targets S3
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14747/full
S241 5A. Fushi tarazu F1-like receptors
S286 Type I receptor serine/threonine kinases
S269 Receptor Guanylyl Cyclase (RGC) family
S269 Transmembrane quanylyl cyclases

S328 CYP2 family
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: and Other Protein Targets. British Journal of Pharmacology (2019) 176, S1–S20Introduction
S370 Tec family
S371 RAF family
S372 Lanosterol biosynthesis pathway
S374 Nucleoside synthesis and metabolism
S376 Paraoxonase (PON) family
S377 Peptidases and proteinases
S377 A1: Pepsin
S377 A22: Presenilin
S378 C14: Caspase
S378 M1: Aminopeptidase N
S379 M2: Angiotensin-converting (ACE and ACE2)
S379 M10: Matrix metallopeptidase
S380 M12: Astacin/Adamalysin
S380 M28: Aminopeptidase Y
S381 M19: Membrane dipeptidase
S381 S1: Chymotrypsin
S382 T1: Proteasome
S382 S8: Subtilisin
S383 S9: Prolyl oligopeptidase
S383 Poly ADP-ribose polymerases
S384 Prolyl hydroxylases
S384 Sphingosine 1-phosphate turnover
S385 Sphingosine kinase
S386 Sphingosine 1-phosphate phosphatase
S387 Sphingosine 1-phosphate lyase
S387 Thyroid hormone turnover
S388 1.14.13.9 Kynurenine 3-monooxygenase
S389 2.5.1.58 Protein farnesyltransferase
S390 3.5.1.- Histone deacetylases (HDACs)
S391 3.5.3.15 Peptidyl arginine deiminases (PADI)
S391 3.6.5.2 Small monomeric GTPases
S391 RAS subfamily
S392 RAB subfamily
S397 Transporters
S399 ATP-binding cassette transporter family
S399 ABCA subfamily
S401 ABCB subfamily
S403 ABCC subfamily
S404 ABCD subfamily of peroxisomal ABC transporters
S405 ABCG subfamily
S406 F-type and V-type ATPases
S406 F-type ATPase
S407 V-type ATPase
S407 P-type ATPases
S407 Na /K -ATPases+ +
S408 Ca2+-ATPases
S408 H /K -ATPases+ +
S408 Cu -ATPases+
S409 Phospholipid-transporting ATPases
S409 SLC superfamily of solute carriers
S410 SLC1 family of amino acid transporters
S410 Glutamate transporter subfamily
S412 Alanine/serine/cysteine transporter subfamily
S413 SLC2 family of hexose and sugar alcohol transporters
S413 Class I transporters
S414 Class II transporters
S415 Proton-coupled inositol transporter
S415 SLC3 and SLC7 families of heteromeric amino acid
transporters (HATs)
S415 SLC3 family
S416 SLC7 family
S417 SLC4 family of bicarbonate transporters
S417 Anion exchangers
S418 Sodium-dependent HCO−3 transporters
S418 SLC5 family of sodium-dependent glucose transporters
S419 Hexose transporter family
S420 Choline transporter
S421 Sodium iodide symporter, sodium-dependent multivitamin
transporter and sodium-coupled monocarboxylate
transporters
S422 Sodium myo-inositol cotransporter transporters
S423 SLC6 neurotransmitter transporter family
S423 Monoamine transporter subfamily
S424 GABA transporter subfamily
S425 Glycine transporter subfamily
S427 Neutral amino acid transporter subfamily
S428 SLC8 family of sodium/calcium exchangers
S429 SLC9 family of sodium/hydrogen exchangers
S429 SLC10 family of sodium-bile acid co-transporters
S431 SLC11 family of proton-coupled metal ion transporters
S431 SLC12 family of cation-coupled chloride transporters
S433 SLC13 family of sodium-dependent sulphate/carboxylate
transporters
S434 SLC14 family of facilitative urea transporters
S435 SLC15 family of peptide transporters
S437 SLC16 family of monocarboxylate transporters
S438 SLC17 phosphate and organic anion transporter family
S438 Type I sodium-phosphate co-transporters
S439 Sialic acid transporter
S439 Vesicular glutamate transporters (VGLUTs)
S440 Vesicular nucleotide transporter
S440 SLC18 family of vesicular amine transporters
S442 SLC19 family of vitamin transporters
S443 SLC20 family of sodium-dependent phosphate transporters
S443 SLC22 family of organic cation and anion transporters
S444 Organic cation transporters (OCT)
S445 Organic zwitterions/cation transporters (OCTN)
S446 Organic anion transporters (OATs)
S446 Urate transporter
S447 Atypical SLC22B subfamily
S448 SLC23 family of ascorbic acid transporters
S449 SLC24 family of sodium/potassium/calcium exchangers
S450 SLC25 family of mitochondrial transporters
S450 Mitochondrial di- and tri-carboxylic acid transporter
subfamily
S451 Mitochondrial amino acid transporter subfamily
S452 Mitochondrial phosphate transporters
S452 Mitochondrial nucleotide transporter subfamily
S453 Mitochondrial uncoupling proteins
S454 Miscellaneous SLC25 mitochondrial transporters
S454 SLC26 family of anion exchangers
S454 Selective sulphate transporters
S455 Chloride/bicarbonate exchangers
S455 Anion channels
S456 Other SLC26 anion exchangers
S457 SLC27 family of fatty acid transporters
S458 SLC28 and SLC29 families of nucleoside transporters
S458 SLC28 family
S459 SLC29 family
S461 SLC30 zinc transporter family
S461 SLC31 family of copper transporters
S462 SLC32 vesicular inhibitory amino acid transporter
S463 SLC33 acetylCoA transporter
S464 SLC34 family of sodium phosphate co-transporters
S465 SLC35 family of nucleotide sugar transporters
S466 SLC36 family of proton-coupled amino acid transporters
S468 SLC37 family of phosphosugar/phosphate exchangers
S468 SLC38 family of sodium-dependent neutral amino acid
transporters
S469 System A-like transporters
S469 System N-like transporters
S470 Orphan SLC38 transporters
S470 SLC39 family of metal ion transporters
S471 SLC40 iron transporter
S472 SLC41 family of divalent cation transporters
S473 SLC42 family of Rhesus glycoprotein ammonium transporters
S473 SLC43 family of large neutral amino acid transporters
S474 SLC44 choline transporter-like family
S475 SLC45 family of putative sugar transporters
S475 SLC46 family of folate transporters
S477    SLC47 family of multidrug and toxin extrusion transporters
S477 SLC48 heme transporter
S478 SLC49 family of FLVCR-related heme transporters
S479 SLC50 sugar transporter
S479 SLC51 family of steroid-derived molecule transporters
S480 SLC52 family of riboﬂavin transporters
S481 SLC53 Phosphate carriers
Searchable database: http://www.guidetopharmacology.org/index.jsp Other protein targets S4
Full Contents of ConciseGuide: http://onlinelibrary.wiley.com/doi/10.1111/bph.14747/full
S369 Janus kinase (JakA) family
S369 Src family
S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2019/20: and Other Protein Targets. British Journal of Pharmacology (2019) 176, S1–S20Introduction
S482 SLC56 Sideroﬂexins
S483 SLC57 NiPA-like magnesium transporter family
S483 SLC58 MagT-like magnesium transporter family
S484 SLC59 Sodium-dependent lysophosphatidylcholine
porter family
S484 SLC60 Glucose transporters
S485 SLC61 Molybdate transporter family
S485 SLC62 Pyrophosphate transporters
S486 SLC63 Sphingosine phosphate
transporters
S486 SLC64 Golgi Ca2+/H+ exchangers
S487 SLC65 NPC-type cholesterol transporters
S488 SLCO family of organic anion transporting
polypeptides
Introduction
In order to allow clarity and consistency in pharmacology, there is
a need for a comprehensive organisation and presentation of the
targets of drugs. This is the philosophy of the IUPHAR/BPS Guide
to PHARMACOLOGY presented on the online free access database
(https://www.guidetopharmacology.org/). This database is sup-
ported by the British Pharmacological Society (BPS), the Interna-
tional Union of Basic and Clinical Pharmacology (IUPHAR), the
University of Edinburgh and previously the Wellcome Trust. Data
included in the Guide to PHARMACOLOGY are derived in large
part from interactions with the subcommittees of the Nomencla-
ture Committee of the International Union of Basic and Clinical
Pharmacology (NC-IUPHAR). A major inﬂuence on the develop-
ment of the database was Tony Harmar (1951-2014), who worked
with a passion to establish the curators as a team of highly in-
formed and informative individuals, with a focus on high-quality
data input, ensuring a suitably validated dataset. The Editors of
the Concise Guide have compiled the individual records, in con-
cert with the team of Curators, drawing on the expert knowledge
of these latter subcommittees. The tables allow an indication of
the status of the nomenclature for the group of targets listed,
usually previously published in Pharmacological Reviews. In
the absence of an established subcommittee, advice from several
prominent, independent experts has generally been obtained to
produce an authoritative consensus on nomenclature, which at-
tempts to ﬁt in within the general guidelines from NC-IUPHAR.
This current edition, the Concise Guide to PHARMACOLOGY
2019/20, is the latest snapshot of the database in print form, fol-
lowing on from the Concise Guide to PHARMACOLOGY 2017/18.
It contains data drawn from the online database as a rapid
overview of the major pharmacological targets. Thus, there are
many fewer targets presented in the Concise Guide compared to
the online database. The priority for inclusion in the Concise
Guide is the presence of quantitative pharmacological data for hu-
man proteins. This means that often orphan family members are
not presented in the Concise Guide, although structural informa-
tion is available on the online database. The organisation of the
data is tabular (where appropriate) with a standardised format,
where possible on a single page, intended to aid understanding
of, and comparison within, a particular target group. The Concise
Guide is intended as an initial resource, with links to additional
reviews and resources for greater depth and information. Phar-
macological and structural data focus primarily on human gene
products, wherever possible, with links to HGNC gene nomen-
clature and UniProt IDs. In a few cases, where data from human
proteins are limited, data from other species are indicated. Phar-
macological tools listed are prioritised on the basis of selectivity
and availability. That is, agents (agonists, antagonists, inhibitors,
activators, etc.) are included where they are both available (by
donation or from commercial sources, now or in the near future)
AND the most selective. The Concise Guide is divided into seven
sections, which comprise pharmacological targets of similar struc-
ture/function. These are G protein-coupled receptors, ion chan-
nels (combining previous records of ligand-gated, voltage-gated
and other ion channels), catalytic receptors, nuclear hormone re-
ceptors, enzymes, transporters and other protein targets. We hope
that the Concise Guide will provide for researchers, teachers and
students a state-of-the art source of accurate, curated information
on the background to their work that they will use in the Introduc-
tions to their Research Papers or Reviews, or in supporting their
teaching and studies. We recommend that any citations to in-
formation in the Concise Guide are presented in the following
format: Alexander SPH et al. (2019). The Concise Guide to PHAR-
MACOLOGY 2019/20: Introduction and Other Protein Targets. Br
J Pharmacol 176: S1–S20. In this overview are listed protein tar-
gets of pharmacological interest, which are not G protein-coupled
receptors, ion channels, nuclear hormone receptors, catalytic re-
ceptors, transporters or enzymes.
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Adiponectin receptors
Other protein targets → Adiponectin receptors
Overview: Adiponectin receptors (provisional nomen-
clature, ENSFM00500000270960) respond to the 30 kDa
complement-related protein hormone adiponectin (also known
as ADIPOQ: adipocyte, C1q and collagen domain-containing pro-
tein; ACRP30, adipose most abundant gene transcript 1; apM-1;
gelatin-binding protein: Q15848) originally cloned from
adipocytes [57]. Although sequence data suggest 7TM domains,
immunological evidence indicates that, contrary to typical 7TM
topology, the carboxyl terminus is extracellular, while the amino
terminus is intracellular [111]. Signalling through these receptors
appears to avoid G proteins; modelling based on the crystal struc-
tures of the adiponectin receptors suggested ceramidase acivity,
which would make these the ﬁrst in a new family of catalytic
receptors [98].
Searchable database: http://www.guidetopharmacology.org/index.jsp Adiponectin receptors S6
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Nomenclature Adipo1 receptor Adipo2 receptor
HGNC, UniProt ADIPOR1, Q96A54 ADIPOR2, Q86V24
Rank order of potency globular adiponectin (ADIPOQ, Q15848) > adiponectin (ADIPOQ, Q15848) globular adiponectin (ADIPOQ, Q15848) = adiponectin (ADIPOQ, Q15848)
Comments: T-Cadherin (CDH13, P55290) has also been suggested to be a receptor for (hexameric) adiponectin [36].
Further reading on Adiponectin receptors
Fisman EZ et al. (2014) Adiponectin: a manifold therapeutic target for metabolic syndrome, dia-
betes, and coronary disease? Cardiovasc Diabetol 13: 103 [PMID:24957699]
Okada-Iwabu M et al. (2018) Structure and function analysis of adiponectin receptors toward de-
velopment of novel antidiabetic agents promoting healthy longevity. Endocr J 65: 971-977
[PMID:30282888]
Ruan H et al. (2016) Adiponectin signaling and function in insulin target tissues. J Mol Cell Biol 8:
101-9 [PMID:26993044]
Wang Y et al. (2017) Cardiovascular Adiponectin Resistance: The Critical Role of Adiponectin Re-
ceptor Modiﬁcation. Trends Endocrinol. Metab. 28: 519-530 [PMID:28473178]
Zhao L et al. (2014) Adiponectin and insulin cross talk: the microvascular connection. Trends Car-
diovasc. Med. 24: 319-24 [PMID:25220977]
Blood coagulation components
Other protein targets → Blood coagulation components
Overview: Coagulation as a process is interpreted as a mechanism for reducing excessive blood loss through the generation of a gel-like clot local to the site of injury. The process involves the activation,
adhesion (see Integrins), degranulation and aggregation of platelets, as well as proteins circulating in the plasma. The coagulation cascade involves multiple proteins being converted to more active forms
from less active precursors, typically through proteolysis (see Proteases). Listed here are the components of the coagulation cascade targetted by agents in current clinical usage.
Nomenclature coagulation factor V coagulation factor VIII serpin family C member 1
HGNC, UniProt F5, P12259 F8, P00451 SERPINC1, P01008
Selective activators – – heparin (pKd 7.8) [29], fondaparinux (pKd 7.5) [72],
dalteparin [35], danaparoid [18, 65], enoxaparin [21],
tinzaparin [22]
Selective inhibitors drotrecogin alfa (Antithrombotic effect thought to
occur via inhibition of factors Va and VIIIa) [39, 40]
drotrecogin alfa (Antithrombotic effect thought to
occur via inhibition of factors Va and VIIIa) [39, 40]
–
Searchable database: http://www.guidetopharmacology.org/index.jsp Blood coagulation components S7
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Further reading on Blood coagulation components
Astermark J. (2015) FVIII inhibitors: pathogenesis and avoidance. Blood 125: 2045-51
[PMID:25712994]
Girolami A et al. (2017) New clotting disorders that cast new light on blood coagulation and may
play a role in clinical practice. J. Thromb. Thrombolysis 44: 71-75 [PMID:28251495]
Rana K et al. (2016) Blood ﬂow and mass transfer regulation of coagulation. Blood Rev. 30: 357-68
[PMID:27133256]
Non-enzymatic BRD containing proteins
Other protein targets → Bromodomain-containing proteins → Non-enzymatic BRD containing proteins
Overview: Bromodomains bind proteins with acetylated lysine residues, such as histones, to regulate gene transcription. Listed herein are examples of bromodomain-containing proteins for which
sufﬁcient pharmacology exists.
Nomenclature bromodomain adjacent
to zinc ﬁnger domain 2A
bromodomain adjacent
to zinc ﬁnger domain 2B
CREB binding protein polybromo 1 SWI/SNF related, matrix
associated, actin dependent
regulator of chromatin, subfamily a,
member 4
HGNC, UniProt BAZ2A, Q9UIF9 BAZ2B, Q9UIF8 CREBBP, Q92793 PBRM1, Q86U86 SMARCA4, P51532
Selective
inhibitors
GSK2801 (pKd 6.6) [85] GSK2801 (Binding) (pKd 6.9) [85] I-CBP112 (pKd 6.8) [84] PFI-3 (Binding) (pKd 7.3) [95] PFI-3 (Binding) (pKd 7.1) [95]
Further reading on Non-enzymatic BRD containing proteins
Fujisawa T et al. (2017) Functions of bromodomain-containing proteins and their roles in home-
ostasis and cancer. Nat. Rev. Mol. Cell Biol. 18: 246-262 [PMID:28053347]
Myrianthopoulos V & Mikros E. (2019) From bench to bedside, via desktop. Recent advances in
the application of cutting-edge in silico tools in the research of drugs targeting bromodomain
modules. Biochem Pharmacol 159: 40-51 [PMID:30414936]
Nicholas DA et al. (2017) BET bromodomain proteins and epigenetic regulation of inﬂamma-
tion: implications for type 2 diabetes and breast cancer. Cell. Mol. Life Sci. 74: 231-243
[PMID:27491296]
Ramadoss M & Mahadevan V. (2018) Targeting the cancer epigenome: synergistic therapy with
bromodomain inhibitors. Drug Discov Today 23: 76-89 [PMID:28943305]
Yang CY et al. (2019) Small-molecule PROTAC degraders of the Bromodomain and Extra Terminal
(BET) proteins - A review. Drug Discov Today Technol 31: 43-51 [PMID:31200858]
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Carrier proteins
Other protein targets → Carrier proteins
Overview: Transthyretin (TTR) is a homo-tetrameric protein
which transports thyroxine in the plasma and cerebrospinal ﬂuid
and retinol (vitamin A) in the plasma. Many disease causing mu-
tations in the protein have been reported, many of which cause
complex dissociation and protein mis-assembly and deposition of
toxic aggregates amyloid ﬁbril formation [73]. These amyloido-
genic mutants are linked to the development of pathological amy-
loidoses, including familial amyloid polyneuropathy (FAP) [6, 16],
familial amyloid cardiomyopathy (FAC) [37], amyloidotic vitre-
ous opacities, carpal tunnel syndrome [63] and others. In old
age, non-mutated TTR can also form pathological amyloid ﬁbrils
[108]. Pharmacological intervention to reduce or prevent TTR dis-
sociation is being pursued as a theapeutic strategy. To date one
small molecule kinetic stabilising molecule (tafamidis) has been
approved for FAP, and is being evaluated in clinical trials for other
TTR amyloidoses.
Nomenclature transthyretin
Common abbreviation TTR
HGNC, UniProt TTR, P02766
Further reading on Carrier proteins
Adams D et al. (2019) Hereditary transthyretin amyloidosis: a model of medical progress for a fatal
disease. Nat Rev Neurol 15: 387-404 [PMID:31209302]
Dellière S et al. (2017) Is transthyretin a good marker of nutritional status? Clin Nutr 36: 364-370
[PMID:27381508]
Galant NJ et al. (2017) Transthyretin amyloidosis: an under-recognized neuropathy and cardiomy-
opathy. Clin. Sci. 131: 395-409 [PMID:28213611]
Yokoyama T & Mizuguchi M. (2018) Inhibition of the Amyloidogenesis of Transthyretin by Natural
Products and Synthetic Compounds. Biol Pharm Bull 41: 979-984 [PMID:29962408]
Ruberg FL et al. (2019) Transthyretin Amyloid Cardiomyopathy: JACC State-of-the-Art Review. J
Am Coll Cardiol 73: 2872-2891 [PMID:31171094]
CD molecules
Other protein targets → CD molecules
Overview: Cluster of differentiation refers to an attempt
to catalogue systematically a series of over 300 cell-surface
proteins associated with immunotyping. Many members of
the group have identiﬁed functions as enzymes (for example,
see CD73 ecto-5’-nucleotidase) or receptors (for example, see
CD41 integrin, alpha 2b subunit). Many CDs are targeted for
therapeutic gain using antibodies for the treatment of prolifera-
tive disorders. A full listing of all the Clusters of Differentiation
proteins is not possible in the Guide to PHARMACOLOGY; listed
herein are selected members of the family targeted for therapeutic
gain.
Searchable database: http://www.guidetopharmacology.org/index.jsp CD molecules S9
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Nomenclature CD2 CD3e CD6 CD20 (membrane-spanning 4-domains,
subfamily A, member 1)
CD33
Common abbreviation – – – – SIGLEC-3
HGNC, UniProt CD2, P06729 CD3E, P07766 CD6, P30203 MS4A1, P11836 CD33, P20138
Selective inhibitors alefacept [19, 62] – – – –
Antibodies – catumaxomab (Binding) [50],
muromonab-CD3 (Binding) [28],
otelixizumab (Binding) [11]
– ofatumumab (Binding) (pKd 9.9) [52],
rituximab (Binding) (pKd 8.5) [91],
ibritumomab tiuxetan (Binding),
obinutuzumab (Binding) [4, 76],
tositumomab (Binding)
lintuzumab (Binding) (pKd ∼10) [12],
gemtuzumab ozogamicin (Binding) [9]
Nomenclature CD52 CD80 CD86 cytotoxic T-lymphocyte-
associated
protein 4 (CD152)
programmed cell death
1 (CD279)
CD300a
Common abbreviation – – – CTLA-4 PD-1 –
HGNC, UniProt CD52, P31358 CD80, P33681 CD86, P42081 CTLA4, P16410 PDCD1, Q15116 CD300A,
Q9UGN4
Endogenous ligands – – – – programmed cell death 1 ligand 1
(CD274, Q9NZQ7) (Binding) 
–
Selective inhibitors – abatacept (pKd ∼7.9) [51, 103] abatacept (pKd ∼7.9)
[51, 103], belatacept [44]
– – –
Antibodies alemtuzumab
(Binding) [26, 86]
– – ipilimumab (Binding)
(pKd >9) [30],
tremelimumab (Binding)
(pKd 8.9) [32]
pembrolizumab (Binding) (pKd∼10) [13], nivolumab (Binding)
(pKd 9.1) [31, 42, 43]
–
Comments: The endogenous ligands for human PD-1 are programmed cell death 1 ligand 1 (PD-L1 aka CD274 (CD274, Q9NZQ7)) and programmed cell death 1 ligand 2 (PD-L2; PDCD1LG2). These
ligands are cell surface peptides, normally involved in immune system regulation. Expression of PD-1 by cancer cells induces immune tolerance and evasion of immune system attack. Anti-PD-1
monoclonal antibodies are used to induce immune checkpoint blockade as a therapeutic intervention in cancer, effectively re-establishing immune vigilance. Pembrolizumab was the ﬁrst anti-PD-1
antibody to be approved by the US FDA.
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Further reading on CD molecules
Gabius HJ et al. (2015) The glycobiology of the CD system: a dictionary for translating marker
designations into glycan/lectin structure and function. Trends Biochem. Sci. 40: 360-76
[PMID:25981696]
Vosoughi T et al. (2019) CDmarkers variations in chronic lymphocytic leukemia: New insights into
prognosis. J Cell Physiol. 234: 19420-39 [PMID:31049958]
Methyllysine reader proteins
Other protein targets → Chromatin-interacting transcriptional repressors → Methyllysine reader proteins
Overview: Methyllysine reader proteins bind to methylated proteins, such as histones, allowing regulation of gene expression.
Nomenclature L3MBTL histone methyl-lysine binding protein 3
HGNC, UniProt L3MBTL3, Q96JM7
Selective agonists UNC1215 [38]
Further reading on Methyllysine reader proteins
Daskalaki MG et al. (2018) Histone methylation and acetylation in macrophages as a mechanism
for regulation of inﬂammatory responses. J Cell Physiol. 233: 6495-9507 [PMID:29574768]
Furuya K et al. (2019) Epigenetic interplays between DNA demethylation and histone methylation
for protecting oncogenesis. J Biochem. 165: 297-299 [PMID:30605533]
Levy D. (2019) Lysine methylation signaling of non-histone proteins in the nucleus. Cell Mol Life
Sci 76: 2873-83 [PMID:31123776]
Li J et al. (2019) Understanding histone H3 lysine 36 methylation and its deregulation in disease.
Cell Mol Life Sci in press [PMID:31147750]
Shafabakhsh R et al. (2019) Role of histone modiﬁcation and DNA methylation in signaling path-
ways involved in diabetic retinopathy. J Cell Physiol. 234: 7839-7846 [PMID:30515789]
Fatty acid-binding proteins
Other protein targets → Fatty acid-binding proteins
Overview: Fatty acid-binding proteins are low molecular weight
(100-130 aa) chaperones for long chain fatty acids, fatty acyl CoA
esters, eicosanoids, retinols, retinoic acids and related metabolites
and are usually regarded as being responsible for allowing the
otherwise hydrophobic ligands to be mobile in aqueous media.
These binding proteins may perform functions extracellularly (e.g.
in plasma) or transport these agents; to the nucleus to interact
with nuclear receptors (principally PPARs and retinoic acid recep-
tors [82]) or for interaction with metabolic enzymes. Although se-
quence homology is limited, crystallographic studies suggest con-
served 3D structures across the group of binding proteins.
Searchable database: http://www.guidetopharmacology.org/index.jsp Fatty acid-binding proteins S11
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Nomenclature fatty acid binding protein 1 fatty acid binding protein 2 fatty acid binding protein 3 fatty acid binding protein 4 fatty acid binding protein 5
HGNC, UniProt FABP1, P07148 FABP2, P12104 FABP3, P05413 FABP4, P15090 FABP5, Q01469
Rank order of potency stearic acid, oleic acid >
palmitic acid, linoleic acid >
arachidonic acid,
α-linolenic acid [77]
stearic acid >
palmitic acid,oleic acid >
linoleic acid > arachidonic acid,
α-linolenic acid [77]
stearic acid, oleic acid,
palmitic acid > linoleic acid,
α-linolenic acid,
arachidonic acid [77]
oleic acid, palmitic acid,
stearic acid, linoleic acid >
α-linolenic acid,
arachidonic acid [77]
–
Inhibitors fenoﬁbrate (pKi 7.6) [14] – Rat,
fenoﬁbric acid (pKi 6.5) [14] –
Rat, HTS01037 (pKi 5.1) [33] –
Mouse
– – – compound 13 (pKi 8.7) [97]
Selective inhibitors – – – HM50316 (pKi >9) [53] –
Comments A broader substrate speciﬁcity
than other FABPs, binding two
fatty acids per protein [101].
Crystal structure of the rat
FABP2 [79].
Crystal structure of the human
FABP3 [112].
– Crystal structure of the
human FABP5 [34].
Nomenclature fatty acid binding protein 6 fatty acid binding protein 7 peripheral myelin protein 2 fatty acid binding protein 9 fatty acid binding protein 12
HGNC, UniProt FABP6, P51161 FABP7, O15540 PMP2, P02689 FABP9, Q0Z7S8 FABP12, A6NFH5
Comments Able to transport bile acids
[113].
Crystal structure of the human
FABP7 [7].
In silico modelling suggests that
PMP2/FABP8 can bind both
fatty acids and cholesterol [58].
– –
Nomenclature retinol binding
protein 1
retinol binding
protein 2
retinol binding protein 3 retinol binding protein 4 retinol binding protein 5 retinol binding protein 7
HGNC, UniProt RBP1, P09455 RBP2, P50120 RBP3, P10745 RBP4, P02753 RBP5, P82980 RBP7, Q96R05
Rank order of potency – stearic acid >
palmitic acid,
oleic acid, linoleic acid,
α-linolenic acid,
arachidonic acid [78]
– – – –
Inhibitors – – – A1120 (pIC50 7.8) [106] – –
Searchable database: http://www.guidetopharmacology.org/index.jsp Fatty acid-binding proteins S12
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Nomenclature retinaldehyde binding protein 1 cellular retinoic acid binding protein 1 cellular retinoic acid binding protein 2
HGNC, UniProt RLBP1, P12271 CRABP1, P29762 CRABP2, P29373
Rank order of potency 11-cis-retinal, 11-cis-retinol > 9-cis-retinal,
13-cis-retinal, 13-cis-retinol,
all-trans-retinal, retinol [17]
tretinoin > alitretinoin
stearic acid > palmitic acid, oleic acid, linoleic acid,
α-linolenic acid, arachidonic acid [78]
–
Comments: Although not tested at all FABPs, BMS309403 exhibits high afﬁnity for FABP4 (pIC50 8.8) compared to FABP3 or FABP5 (pIC50 <6.6) [23, 97]. HTS01037 is reported to interfere with FABP4
action [33]. Ibuprofen displays some selectivity for FABP4 (pIC50 5.5) relative to FABP3 (pIC50 3.5) and FABP5 (pIC50 3.8) [56]. Fenoﬁbric acid displays some selectivity for FABP5 (pIC50 5.5) relative to
FABP3 (pIC50 4.5) and FABP4 (pIC50 4.6) [56]. Multiple pseudogenes for the FABPs have been identiﬁed in the human genome.
Further reading on Fatty acid-binding proteins
Gajda AM et al. (2015) Enterocyte fatty acid-binding proteins (FABPs): different functions of liver
and intestinal FABPs in the intestine. Prostaglandins Leukot. Essent. Fatty Acids 93: 9-16
[PMID:25458898]
Glatz JF. (2015) Lipids and lipid binding proteins: a perfect match. Prostaglandins Leukot Essent Fatty
Acids 93: 45-9 [PMID:25154384]
Hotamisligil GS et al. (2015) Metabolic functions of FABPs–mechanisms and therapeutic implica-
tions. Nat Rev Endocrinol 11: 592-605 [PMID:26260145]
Matsumata M et al. (2016) Fatty acid binding proteins and the nervous system: Their impact on
mental conditions. Neurosci. Res. 102: 47-55 [PMID:25205626]
Osumi T et al. (2016) Heart lipid droplets and lipid droplet-binding proteins: Biochemistry, physi-
ology, and pathology. Exp. Cell Res. 340: 198-204 [PMID:26524506]
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Notch receptors
Other protein targets → Notch receptors
Overview: The canonical Notch signalling pathway has four
type I transmembrane Notch receptors (Notch1-4) and ﬁve lig-
ands (DLL1, 2 and 3, and Jagged 1-2). Each member of this highly
conserved receptor family plays a unique role in cell-fate determi-
nation during embryogenesis, differentiation, tissue patterning,
proliferation and cell death [3]. As the Notch ligands are also
membrane bound, cells have to be in close proximity for receptor-
ligand interactions to occur. Cleavage of the intracellular domain
(ICD) of activated Notch receptors by γ-secretase is required for
downstream signalling and Notch-induced transcriptional modu-
lation [20, 66, 83, 109]. This is why γ-secretase inhibitors can be
used to downregulate Notch signalling and explains their anti-
cancer action. One such small molecule is RO4929097 [54],
although development of this compound has been terminated
following an unsuccessful Phase II single agent clinical trial in
metastatic colorectal cancer [94].
Aberrant Notch signalling is implicated in a number of human
cancers [46, 68, 88, 104], with demcizumab and tarextumab iden-
tiﬁed as antibody inhibitors of ligand:receptor binding [74].
Nomenclature notch receptor 1 notch receptor 2 notch receptor 3 notch receptor 4
HGNC, UniProt NOTCH1, P46531 NOTCH2, Q04721 NOTCH3, Q9UM47 NOTCH4, Q99466
Comments Various types of activating and inactivating NOTCH1
mutations have been reported to be associated with human
diseases, for example: aortic valve disease [25, 61],
Adams-Oliver syndrome 5 [92], T-cell acute lymphoblastic
leukemia (T-ALL) [107], chronic lymphocytic leukemia (CLL)
[75] and head and neck squamous cell carcinoma [1, 93].
– – Notch receptor 4 is a potential therapeutic
molecular target for triple-negative breast cancer
[47, 64].
Further reading on Notch receptors
Arumugam TV et al. (2018) Notch signaling and neuronal death in stroke. Prog. Neurobiol. 165-167:
103-116 [PMID:29574014]
Borggrefe T et al. (2016) The Notch intracellular domain integrates signals from Wnt, Hedgehog,
TGFβ/BMP and hypoxia pathways. Biochim. Biophys. Acta 1863: 303-13 [PMID:26592459]
Palmer WH et al. (2015) Ligand-Independent Mechanisms of Notch Activity. Trends Cell Biol. 25:
697-707 [PMID:26437585]
Previs RA et al. (2015) Molecular pathways: translational and therapeutic implications of the Notch
signaling pathway in cancer. Clin. Cancer Res. 21: 955-61 [PMID:25388163]
Takebe N et al. (2015) Targeting Notch, Hedgehog, and Wnt pathways in cancer stem cells: clinical
update. Nat Rev Clin Oncol 12: 445-64 [PMID:25850553]
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Regulators of G protein Signaling (RGS) proteins
Other protein targets → Regulators of G protein Signaling (RGS) proteins
Overview: Regulators of G protein signalling (RGS) proteins dis-
play a common RGS domain that interacts with the GTP-bound
Gα subunits of heterotrimeric G proteins, enhancing GTP hy-
drolysis by stabilising the transition state [8, 99, 100], leading
to a termination of GPCR signalling. Interactions through pro-
tein:protein interactions of many RGS proteins have been iden-
tiﬁed for targets other than heteromeric G proteins. Sequence
analysis of the 20 RGS proteins suggests four families of RGS: RZ,
R4, R7 and R12 families. Many of these proteins have been iden-
tiﬁed to have effects other than through targetting G proteins.
Included here is RGS4 for which a number of pharmacological
inhibitors have been described.
RZ family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → RZ family
Overview: The RZ family of RGS proteins is less well character-
ized than the other families [69]. It consists of RGS17 (also known
as RGSZ2), RGS19 (also known as GAIP) and RGS20 (with sev-
eral splice variants including RGSZ1 and Ret-RGS). All members
contain an N-terminal cysteine string motif [49] which is a site of
palmitoylation and could serve functions in membrane targeting,
protein stability or aid protein-protein interactions [2, 49]. How-
ever, the function in the case of RZ family RGS proteins is not
yet fully understood. Members of the RZ family of RGS proteins
are the only RGS proteins that have selective GTPase activating-
protein (GAP) activity for Gαz, a function that resulted in the
name of the family [27, 59, 105, 110]. However, the members
of the RZ family are able to also GAP Gαi/o members with varying
selectivity.
Nomenclature regulator of G-protein signaling 17 regulator of G-protein signaling 19 regulator of G-protein signaling 20
Common abbreviation RGS17 RGS19 RGS20
HGNC, UniProt RGS17, Q9UGC6 RGS19, P49795 RGS20, O76081
R4 family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → R4 family
Overview: This is the largest family of RGS proteins.
Searchable database: http://www.guidetopharmacology.org/index.jsp R4 family S15
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Nomenclature regulator of G-protein signaling 1 regulator of G-protein signaling 2 regulator of G-protein signaling 3 regulator of G-protein signaling 4
Common abbreviation RGS1 RGS2 RGS3 RGS4
HGNC, UniProt RGS1, Q08116 RGS2, P41220 RGS3, P49796 RGS4, P49798
Selective inhibitors – – – RGS4 inhibitor 11b (pIC50 7.8) [102],
CCG-50014 (pIC50 7.5) [10, 102],
RGS4 inhibitor 13 (pIC50 7.3) [102]
Nomenclature regulator of G-protein
signaling 5
regulator of G-protein
signaling 8
regulator of G-protein
signaling 13
regulator of G-protein
signaling 16
regulator of G-protein
signaling 18
regulator of G-protein
signaling 21
Common abbreviation RGS5 RGS8 RGS13 RGS16 RGS18 RGS21
HGNC, UniProt RGS5, O15539 RGS8, P57771 RGS13, O14921 RGS16, O15492 RGS18, Q9NS28 RGS21, Q2M5E4
R7 family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → R7 family
Overview: This family of RGS proteins shows some selectivity for Gai/o proteins.
Nomenclature regulator of G-protein signaling 6 regulator of G-protein signaling 7 regulator of G-protein signaling 9 regulator of G-protein signaling 11
Common abbreviation RGS6 RGS7 RGS9 RGS11
HGNC, UniProt RGS6, P49758 RGS7, P49802 RGS9, O75916 RGS11, O94810
Searchable database: http://www.guidetopharmacology.org/index.jsp R7 family S16
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R12 family
Other protein targets → Regulators of G protein Signaling (RGS) proteins → R12 family
Overview: The R12 family consists of RGS10, 12 and 14. RGS12
and 14 are large proteins with additional domains that can par-
ticipate in protein-protein interactions and other functions. In
contrast, RGS10 is a small protein consisting of the RGS domain
and small N- and C-termini, similar to members of the R4 family.
However, sequence homology of the RGS10 RGS domain clearly
places it in the R12 family [45]. The Gαi/o-Loco (GoLoco) motif in
RGS12 and 14 has GDI activity (for Guanine nucleotide Dissocia-
tion Inhibitor) towardsGαi1, Gαi2 andGαi3 [41, 87]. Through this
activity RGS12 and RGS14 can inhibit G protein signaling both by
accelerating GTP hydrolysis and by preventing G protein activa-
tion. Splice variants of RGS12 and RGS14 also contain membrane
targeting and protein-protein interaction domains [80, 89, 90].
Nomenclature regulator of G-protein signaling 10 regulator of G-protein signaling 12 regulator of G-protein signaling 14
Common abbreviation RGS10 RGS12 RGS14
HGNC, UniProt RGS10, O43665 RGS12, O14924 RGS14, O43566
Further reading on Regulators of G protein Signaling (RGS) proteins
Alqinyah M et al. (2018) Regulating the regulators: Epigenetic, transcriptional, and post-
translational regulation of RGS proteins. Cell. Signal. 42: 77-87 [PMID:29042285]
Neubig RR et al. (2002) Regulators of G-protein signalling as new central nervous system drug tar-
gets. Nat Rev Drug Discov 1: 187-97 [PMID:12120503]
Sethakorn N et al. (2010) Non-canonical functions of RGS proteins. Cell. Signal. 22: 1274-81
[PMID:20363320]
Sjögren B. (2017) The evolution of regulators of G protein signalling proteins as drug targets - 20
years in the making: IUPHAR Review 21. Br. J. Pharmacol. 174: 427-437 [PMID:28098342]
Sjögren B et al. (2010) Thinking outside of the "RGS box": new approaches to therapeutic targeting
of regulators of G protein signaling. Mol. Pharmacol. 78: 550-7 [PMID:20664002]
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Sigma receptors
Other protein targets → Sigma receptors
Overview: Although termed ’receptors’, the evidence for coupling through conventional signalling pathways is lacking. Initially described as a subtype of opioid receptors, there is only a modest
pharmacological overlap and no structural convergence with the G protein-coupled receptors; the crystal structure of the sigma1 receptor [81] suggests a trimeric structure of a single short transmembrane
domain traversing the endoplasmic reticulum membrane, with the bulk of the protein facing the cytosol. A wide range of compounds, ranging from psychoactive agents to antihistamines, have been
observed to bind to these sites.
Nomenclature sigma non-opioid intracellular receptor 1 σ2
HGNC, UniProt SIGMAR1, Q99720 TMEM97, Q5BJF2
Agonists – 1,3-ditolylguanidine [48] – Guinea pig
Selective agonists PRE-084 [96], (+)-SKF 10.047 –
Antagonists – SM 21 (pIC50 7.2) [55]
Selective antagonists NE-100 (pIC50 8.4) [70], BD-1047 (pIC50 7.4) [60] –
Labelled ligands [3H]pentazocine (Agonist) [3H]-di-o-tolylguanidine (Agonist)
Comments – The sigma2 receptor has been reported to be TMEM97 [5], a 4TM protein partner of NPC1, the Niemann-Pick C1
protein, a 13TM cholesterol-binding protein.
Comments: (-)-pentazocine also shows activity at opioid receptors. The sigma2 receptor has recently been reported to be TMEM97 [5], a 4TM protein partner of NPC1, the Niemann-Pick C1 protein, a
13TM cholesterol-binding protein.
Further reading on Sigma receptors
Chu UB et al. (2016) Biochemical Pharmacology of the Sigma-1 Receptor. Mol. Pharmacol. 89:
142-53 [PMID:26560551]
Gris G et al. (2015) Sigma-1 receptor and inﬂammatory pain. Inﬂamm. Res. 64: 377-81
[PMID:25902777]
Rousseaux CG et al. (2016) Sigma receptors [σRs]: biology in normal and diseased states. J. Recept.
Signal Transduct. Res. 36: 327-388 [PMID:26056947]
Sambo DO et al. (2018) The sigma-1 receptor as a regulator of dopamine neurotransmission: A
potential therapeutic target for methamphetamine addiction. Pharmacol Ther 186: 152-167
[PMID:29360540]
Su TP et al. (2016) The Sigma-1 Receptor as a Pluripotent Modulator in Living Systems. Trends
Pharmacol. Sci. 37: 262-278 [PMID:26869505]
Vavers E et al. (2019) Allosteric Modulators of Sigma-1 Receptor: A Review. Front Pharmacol 10: 223
[PMID:30941035]
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Tubulins
Other protein targets → Tubulins
Overview: Tubulins are a family of intracellular proteins most commonly associated with microtubules, part of the cytoskeleton. They are exploited for therapeutic gain in cancer chemotherapy as
targets for agents derived from a variety of natural products: taxanes, colchicine and vinca alkaloids. These are thought to act primarily through β-tubulin, thereby interfering with the normal processes
of tubulin polymer formation and disassembly.
Nomenclature tubulin alpha 1a tubulin alpha 4a tubulin beta class I tubulin beta 3 class III tubulin beta 4B class IVb tubulin beta 8 class VIII
HGNC, UniProt TUBA1A, Q71U36 TUBA4A, P68366 TUBB, P07437 TUBB3, Q13509 TUBB4B, P68371 TUBB8, Q3ZCM7
Inhibitors – – vinblastine (pIC50 9), eribulin (pIC50
8.2) [67], paclitaxel (Mitotic cell cycle
arrest in A431 cells) (pEC50 8.1) [71],
colchicine (pIC50 8) [15], cabazitaxel,
docetaxel, ixabepilone, vincristine
combretastatin A4 (pIC50
8.2) [24]
– –
Further reading on Tubulins
Arnst KE et al. (2019) Current advances of tubulin inhibitors as dual acting small molecules for
cancer therapy. Med Res Rev 39: 1398-1426 [PMID:30746734]
Eshun-Wilson L. (2019) Effects of alpha-tubulin acetylation on microtubule structure and stability.
Proc Natl Acad Sci U S A 116: 10366-10371 [PMID:31072936]
Gadadhar S et al. (2017) The tubulin code at a glance. J. Cell. Sci. 130: 1347-1353 [PMID:28325758]
Magiera MM et al. (2018) Tubulin Posttranslational Modiﬁcations and Emerging Links to Human
Disease. Cell 173: 1323-1327 [PMID:29856952]
Penna LS et al. (2017) Anti-mitotic agents: Are they emerging molecules for cancer treatment?
Pharmacol. Ther. 173: 67-82 [PMID:28174095]
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